<p>Actinium Pharmaceuticals，这家医疗行业公司，今天被华尔街分析师重新评估。来自 JonesTrading 的分析师 Justin Walsh 重申了对该股票的买入评级，并设定了 9.00 美元的目标价。</p>
<h3>享受 TipRanks Premium 50% 的折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的位置</li>
</ul>
<p>Justin Walsh 给予买入评级是基于多种因素的综合考虑，主要集中在 Actinium Pharmaceuticals 的 ATNM-400 的有前景的临床前数据上。该资产在多种乳腺癌模型中显示出显著潜力，包括对常见治疗如他莫昔芬和曲妥珠单抗耐药的模型。这种在大实体肿瘤适应症中的广泛抗肿瘤活性表明，ATNM-400 在进入临床试验后可能提供可观的发展机会。</p>
<p>此外，ATNM-400 在耐药乳腺癌细胞中的结合和内化能力，以及在耐药病例中与曲妥珠单抗联合使用时的协同效应，进一步支持了其潜在疗效。这些有希望的结果，加上公司稳健的财务状况，促成了对 Actinium Pharmaceuticals 的乐观前景和买入评级。</p>
<p>在 12 月 12 日发布的另一份报告中，Maxim Group 也维持了对该股票的买入评级，目标价为 5.00 美元。</p>

Actinium制药

<p>分析师 Justin Walsh 来自 JonesTrading 重申了对 Actinium Pharmaceuticals 的买入评级，目标价为 9.00 美元，原因是 ATNM-400 在乳腺癌模型中的有希望的临床前数据。该资产在耐药病例中显示出潜力，并与曲妥珠单抗具有协同效应。Maxim Group 也维持了买入评级，目标价为 5.00 美元，强调了公司的稳健财务状况</p>

<p>Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $9.00 price target.</p>
<div class="lb-trans"><p>Actinium Pharmaceuticals，这家医疗行业公司，今天被华尔街分析师重新评估。来自 JonesTrading 的分析师 Justin Walsh 重申了对该股票的买入评级，并设定了 9.00 美元的目标价。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 的折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的位置</li>
</ul>
</div><p>Justin Walsh has given his Buy rating due to a combination of factors, primarily focusing on the promising preclinical data of Actinium Pharmaceuticals’ ATNM-400. The asset has shown significant potential in various breast cancer models, including those resistant to common treatments like tamoxifen and trastuzumab. This broad anti-tumor activity in large solid tumor indications suggests that ATNM-400 could offer substantial development opportunities once it progresses to clinical trials.</p>
<div class="lb-trans"><p>Justin Walsh 给予买入评级是基于多种因素的综合考虑，主要集中在 Actinium Pharmaceuticals 的 ATNM-400 的有前景的临床前数据上。该资产在多种乳腺癌模型中显示出显著潜力，包括对常见治疗如他莫昔芬和曲妥珠单抗耐药的模型。这种在大实体肿瘤适应症中的广泛抗肿瘤活性表明，ATNM-400 在进入临床试验后可能提供可观的发展机会。</p>
</div><p>Moreover, ATNM-400’s ability to bind and internalize in resistant breast cancer cells, along with its synergistic effects when combined with trastuzumab in resistant cases, further supports its potential efficacy. These promising results, combined with the company’s solid financial position, contribute to the optimistic outlook and the Buy rating for Actinium Pharmaceuticals.</p>
<div class="lb-trans"><p>此外，ATNM-400 在耐药乳腺癌细胞中的结合和内化能力，以及在耐药病例中与曲妥珠单抗联合使用时的协同效应，进一步支持了其潜在疗效。这些有希望的结果，加上公司稳健的财务状况，促成了对 Actinium Pharmaceuticals 的乐观前景和买入评级。</p>
</div><p>In another report released on December 12, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.</p>
<div class="lb-trans"><p>在 12 月 12 日发布的另一份报告中，Maxim Group 也维持了对该股票的买入评级，目标价为 5.00 美元。</p>
</div>

Actinium 制药的 ATNM-400 展现出有前景的潜力，推动了买入评级